BIOCYTOGEN PHARMA. H YC1

Research BIOCYTOGEN PHARMA. H YC1 (I54) on Bullrun: valuation model: 48.8% overvalued, market cap EUR 2.28B, P/E 85.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerI54
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Valuation signal48.8% overvalued
• Market capEUR 2.28B
• P/E85.8
• Financial periodFY2025
• RevenueEUR 1.38B
• Revenue growth40.6%
• Net incomeEUR 173.20M
• Free cash flowEUR 282.43M
• Gross margin75.8%

Valuation Snapshot

Bullrun's latest valuation model marks BIOCYTOGEN PHARMA. H YC1 as 48.8% overvalued; latest market cap is EUR 2.28B; P/E is 85.8.

About BIOCYTOGEN PHARMA. H YC1

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other.

Frequently asked questions

Is BIOCYTOGEN PHARMA. H YC1 overvalued or undervalued?

Bullrun's valuation model currently marks BIOCYTOGEN PHARMA. H YC1 as 48.8% overvalued.

What is BIOCYTOGEN PHARMA. H YC1's market cap?

BIOCYTOGEN PHARMA. H YC1's market capitalization is EUR 2.28B.

What is BIOCYTOGEN PHARMA. H YC1's P/E ratio?

BIOCYTOGEN PHARMA. H YC1's price-to-earnings (P/E) ratio is 85.8.

What does BIOCYTOGEN PHARMA. H YC1 do?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing;